The duration of impairment of autonomic control after anticholinergic drug administration in humans.
Impaired parasympathetic control of heart rate is associated with increased incidence of cardiac dysrhythmias and ischemia. Anticholinergic drugs, commonly administered during reversal of neuromuscular blockade, suppress parasympathetic control in the early postoperative period. This could potentially be detrimental in patients at risk of cardiovascular complications. The duration of parasympathetic impairment by two anticholinergic drugs were compared in this double-blind randomized cross-over study. Fourteen healthy volunteers received a single intravenous injection of atropine 20 micrograms/kg or glycopyrrolate 8 micrograms/kg during two different study sessions. The methods of spontaneous baroreflex analysis and spectral analysis of heart rate variability generated indices of beat-by-beat parasympathetic modulation of heart rate. Both drugs resulted in a marked decrease in baroreflex sensitivity and high-frequency heart rate variability. The times to return to baseline values were approximately doubled after atropine compared to glycopyrrolate (177 +/- 22 vs 82 +/- 8 min for baroreflex sensitivity, 212 +/- 16 vs 111 +/- 14 min for high-frequency power, and 171 +/- 18 vs 95 +/- 18 min for high-frequency power normalized to total power; P < 0.01 for all variables). Atropine leads to more prolonged impairment of parasympathetic control than equipotent doses of glycopyrrolate, and its use may thus be less desirable in high-risk patients in the early postoperative period.
Parlow
J L
JL
Department of Anaesthesia, Queen's University, Kingston, Ontario, Canada.
van Vlymen
J M
JM
Odell
M J
MJ
D001285:Atropine / Q000008:administration & dosage / Q000009:adverse effects; D017704:Baroreflex / Q000502:physiology; D001794:Blood Pressure / Q000187:drug effects; D018680:Cholinergic Antagonists / Q000008:administration & dosage / Q000009:adverse effects*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D006024:Glycopyrrolate / Q000008:administration & dosage / Q000009:adverse effects; D006321:Heart / Q000294:innervation*; D006339:Heart Rate / Q000502:physiology; D006801:Humans; D010275:Parasympathetic Nervous System / Q000187:drug effects / Q000503:physiopathology*; D013997:Time Factors
D018680:Cholinergic Antagonists; D001285:Atropine; D006024:Glycopyrrolate